Resolution: standard / high
Figure 2.
Incremental costs (or cost savings) associated with use of RDTs when malaria is confirmed
in varying proportions of patients for two ACTs (artesunate plus sulfadoxine-pyrimethamine
and artemether-lumefantrine); excluding 'other recurrent costs'.
Zikusooka et al. Malaria Journal 2008 7:176 doi:10.1186/1475-2875-7-176
Download authors' original image